|
| Study | Marker | Publication year | Number of patients (NMIBC/MIBC) | Threshold | Assessment period | Main findings |
|
| Hilmy et al. [35] | CRP | 2005 | 105 (76/29) | 1.0 mg/dL | Before surgery (TURBT) | Elevated preoperative CRP (>1) was independently associated with worse CSS |
|
| Yoshida et al. [36] | CRP | 2008 | 88 (0/88) | 0.5 mg/dL | Before radiochemotherapy | Elevated preoperative CRP (≥0.5) was independent predictor of worse CSS |
|
| Gakis et al. [37] | CRP | 2011 | 246 (0/246) | 0.5 mg/dL or continuous | 1–3 days before RC | Patients with elevated CRP (>0.5) showed advanced age, more extravesical disease, larger tumor size, node positive disease, and positive surgical margin and increased CRP (continuous) was independent predictor of worse CSS |
|
| Hwang et al. [39] | GPS, Albumin | 2012 | 67 (0/67) | 1.0 mg/dL (CRP)
3.5 g/dL (Albumin) | 1 day before first chemotherapy cycle | Hypoalbuminemia (<3.5) and GPS 2 was independently associated with reduced PFS and OS, respectively |
|
| Ku et al. [46] | Albumin
Neutrophil count
Platelet count | 2015 | 419 (173/246) | 3.5 g/dL (Albumin)
7500/uL (Neutrophil)
400 × 105/ul (Platelet) | Before RC | Low albumin, high lymphocyte count, and high platelet count were significantly
associated with worse OS and CSS |
|
| Gondo et al. [38] | NLR | 2012 | 189 (62/127) | 2.5 | Before RC | Elevated NLR (≥2.5) was an independent predictor of worse DSS |
|
| Demirtaş et al. [40] | NLR | 2013 | 201 (35/166) | 2.5 | Before RC | Elevated NLR (>2.5) was not associated with overall survival |
|
| Hermanns et al. [41] | NLR | 2014 | 424 | 3 | Before RC | Patients with elevated NLR (≥3) significantly showed more advanced pathologic tumor stage
Elevated NLR (≥3) was significantly associated with RFS, OS, and CSS |
|
| Kaynar et al. [42] | NLR | 2014 | 291 (192/99) | NA (continuous) | 1 day before surgery (TURBT or RC) | Patients with MIBC showed significantly higher NLR value than those with NMIBC
Also, higher NLR significantly correlated with advanced age, larger tumor size, and aggressive tumor invasiveness |
|
| Potretzke et al. [43] | NLR | 2014 | 102 (31/71) | NA (continuous) | Before RC | NLR was significant predictor of pathological upstaging after RC; also, patients with pathological upstaging to ≥pT3 had a significantly greater NLR compared to patents who remained at ≤pT2 |
|
| Viers et al. [44] | NLR | 2014 | 899 (392/507) | 2.7 | Within 90 days before RC | Elevated NLR (≥2.7) was significantly associated with adverse pathologic finding (higher pathologic tumor stage, node positive, and larger tumor size); increased NLR (continuous) was independently associated with worse RFS, OS, and CSS |
|
| Mano et al. [47] | NLR | 2015 | 107 (107/0) | 2.41 (for progression)
2.43 (for recurrence) | Before TURBT | Elevated NLR (>2.41) showed more pT1 tumors and was significantly associated with disease progression;
elevated NLR (>2.43) was independent predictor of disease recurrence |
|
| Seah et al. [48] | NLR | 2015 | 26 (0/26) | NA | Before NACH, during NACH, and after RC | Significant NLR decrease from before NACH to before RC was observed in patients with pathological response after NACH and RC |
|
| Kang et al. [45] | NLR | 2015 | 385 | 2.0 (postoperative)
2.1 (preoperative) | Within 1 month before RC and within 3 months after RC | Patients with elevated postoperative NLR (≥2.0) had higher rates of ≥pT3, LVI, and positive lymph node and elevated postoperative NLR (≥2.0) was an independent predictor of OS and CSS; also, patients with perioperative continuous elevated NLR (2.1–>2.0) showed worse OS and CSS compared with other change groups |
|
